14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CBIO vs BOLD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) captures the overall head-to-head institutional edge over Crescent Biopharma, Inc. (CBIO) on higher Unified Composite conviction (36.8/100 SELL vs. 49.2/100 HOLD) after splitting the core matrix 4–2 (led by Profitability & Quality, Options & Positioning), while CBIO wins 3–2 across the 6-pillar growth and valuation breakdown. CBIO trades at $13.00 (N/M Forward P/E, -1228.4% operating margin) versus BOLD at $2.32 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While CBIO currently prints a higher short-term Unified Composite Score (49.2/100 HOLD vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (4–2 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -1228.4% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
Technical & Structure Timing Caution: CBIO is currently in a Breakdown options structure phase (RSI 45.1); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CBIO vs BOLD. Trailing 12-month operating profitability (CBIO -1228.4% vs BOLD 0.0%) and valuation multiples (CBIO N/M vs BOLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $56.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CBIO vs BOLD Key Questions & Quantitative Answers
As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) captures the overall head-to-head institutional edge over Crescent Biopharma, Inc. (CBIO) on higher Unified Composite conviction (36.8/100 SELL vs. 49.2/100 HOLD) after splitting the core matrix 4–2 (led by Profitability & Quality, Options & Positioning), while CBIO wins 3–2 across the 6-pillar growth and valuation breakdown. CBIO trades at $13.00 (N/M Forward P/E, -1228.4% operating margin) versus BOLD at $2.32 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CBIO currently prints a higher short-term Unified Composite Score (49.2/100 HOLD vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (4–2 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -1228.4% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: CBIO is currently in a Breakdown options structure phase (RSI 45.1); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CBIO leads the Growth & Scale pillar: CBIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $15M TTM revenue (100.0% gross margin, -1228.4% operating margin), compared with BOLD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CBIO generates $15M in USD-normalized revenue versus N/A for BOLD. In operating R&D and SG&A reinvestment, CBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BOLD.
CBIO screens cheaper on headline valuation multiples. CBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.8x EV/Revenue (unreported FCF margin), whereas BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CBIO (-160.8% ROE) versus BOLD (-64.6% ROE) capital efficiency.
In options market volatility and institutional positioning, CBIO carries 215.9% implied volatility (98th %ile, Extreme (>80th %ile)), a 1.00x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.18β · 60% Vol realized risk). By comparison, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.